Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

New US Cholesterol Guidelines Hit PCSK9s Hard On Pricing, Value

Nov 19 2018

• By Emily Hayes

Human Heart network

Related Content

Time, And Price, Are Right To Prescribe Statins To the Masses

Dec 02 2013

PCSK9 Inhibitor Labeling Parity Is Within Reach As Praluent And Repatha Strive To Make Commercial Case

Aug 20 2018

Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use

Oct 25 2018

Sanofi's Vaccines Performance Helps Offset Diabetes Decline

Nov 01 2018

Merck Fails To Win Zetia/Vytorin CV Risk Reduction Claim

Feb 17 2016

Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?

Mar 18 2017

Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It

May 01 2018

PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent

Mar 13 2018

PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes

Aug 05 2017

Related Companies

Amgen, Inc.

Sanofi

Amarin Corp plc

Merck & Co., Inc.

Regeneron Pharmaceuticals, Inc.

Stanford University

Additional Topics

Cost Effectiveness Pricing Strategies Market Access Research & Development Cardiovascular BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.